IL5

Interleukin-5 · P05113 · IL5 on Sugi Atlas →

3,771 patent compounds predicted against IL5, 3,366 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dexbudesonide (SCHEMBL4095)	1.00	1/20
Budesonide (SCHEMBL4096)	1.00	1/20
Budesonide (SCHEMBL19635)	1.00	1/20
Dexbudesonide (SCHEMBL865033)	1.00	1/20
Budesonide (SCHEMBL1130417)	1.00	1/20
Dexbudesonide (SCHEMBL1560710)	1.00	1/20
Budesonide (SCHEMBL1786635)	1.00	1/20
Budesonide (SCHEMBL1888070)	1.00	1/20
Budesonide (SCHEMBL8056801)	1.00	1/20
Budesonide (SCHEMBL9763339)	1.00	1/20
Budesonide (SCHEMBL10002031)	1.00	1/20
Budesonide (SCHEMBL10020756)	1.00	1/20
Budesonide (SCHEMBL10051995)	1.00	1/20
Budesonide (SCHEMBL10801498)	1.00	1/20
Dexbudesonide (SCHEMBL646426)	0.98	1/20
Dexbudesonide (SCHEMBL868335)	0.98	1/20
Budesonide (SCHEMBL868336)	0.98	1/20
Dexbudesonide (SCHEMBL3786522)	0.98	1/20
Dexbudesonide (SCHEMBL141510)	0.97	1/20
Budesonide (SCHEMBL4448854)	0.97	1/20

Clinical trials — most relevant to IL5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
th2 Modulation CRSwNP	PHASE4	UNKNOWN
BenRalizumab Effect on Airway Remodeling in Severe asTHma	PHASE4	UNKNOWN
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil	PHASE4	UNKNOWN
Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines	PHASE4	COMPLETED
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.	PHASE4	UNKNOWN
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma	PHASE4	COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma	PHASE3	COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma	PHASE3	COMPLETED
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma	PHASE2	RECRUITING
Japanese Phase 1 Study of Mepolizumab	PHASE1	COMPLETED
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)	nan	UNKNOWN
Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins	nan	COMPLETED
Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis	nan	UNKNOWN
Non-Eosinophilic Biological Effects of IL-5	nan	UNKNOWN
Role of T-Cells in Asthma	nan	COMPLETED
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)	nan	UNKNOWN
Charcot Leyden Crystals in Pathology	nan	COMPLETED
Exploring Asthma Exacerbations in Mepolizumab Treated Patients	nan	COMPLETED
Effectiveness of Anti-IL-5/IL5R Inhibitors	nan	COMPLETED
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)	nan	COMPLETED
To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong	nan	RECRUITING
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma	nan	ACTIVE_NOT_RECRUITING
Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting	nan	UNKNOWN
Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps	nan	COMPLETED
Using Exercise-testing to Explore Patient Differences in Severe Asthma	nan	ACTIVE_NOT_RECRUITING
Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes	nan	NOT_YET_RECRUITING
Immune Dysregulation in Children and Adults With Asthma	nan	COMPLETED
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma	nan	UNKNOWN
Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).	nan	UNKNOWN
Clinical Relevance of Small Airways Disease in Severe Asthma Patients Treated With Anti-InterLeukin-5 Therapy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IL5 binder may also engage these)

Protein	Name	Similarity
P46685	—	1.000	P46685 →
Q9ESI9	—	1.000	Q9ESI9 →
P52173	—	1.000	P52173 →
P48093	—	1.000	P48093 →
Q9XT91	—	1.000	Q9XT91 →
Q28586	—	0.999	Q28586 →
O02699	—	0.999	O02699 →
Q08125	—	0.998	Q08125 →
Q6EBC2	—	0.998	Q6EBC2 →
O77515	—	0.997	O77515 →
Q95J76	—	0.997	Q95J76 →
Q62575	—	0.997	Q62575 →
Q9MYM5	—	0.997	Q9MYM5 →
Q5I6E4	—	0.996	Q5I6E4 →
Q76LU6	—	0.996	Q76LU6 →
P47966	—	0.996	P47966 →
P15247	—	0.996	P15247 →
Q06435	—	0.996	Q06435 →
P04401	—	0.996	P04401 →
Q08081	—	0.995	Q08081 →
P79155	—	0.995	P79155 →
P41159	—	0.995	P41159 →
IL2	Interleukin-2	0.995	landscape →
P51744	—	0.994	P51744 →
O08987	—	0.994	O08987 →
O97513	—	0.994	O97513 →
P11052	—	0.994	P11052 →
Q9JJY9	—	0.994	Q9JJY9 →
Q9XSW9	—	0.994	Q9XSW9 →
Q95J68	—	0.994	Q95J68 →